Volume : 10, Issue : 01, January – 2023

Title:

37.AN INTRODUCTION TO HYPERLIPIDEMIA AND CURRENT TRENDS IN MANAGEMENT OF HYPERLIPIDEMIA – A REVIEW ARTICLE
‬

Authors :

J S Venkatesh, Upendra N, A S Gayathri Lakshmi, Anandhu RS, Alby Sunny, Anju Jayan

Abstract :

Hyperlipidemia is a condition characterized by an elevation in one or more plasma lipids, such as triglycerides, cholesterol, cholesterol esters, phospholipids, and/or plasma lipoproteins, such as very low-density lipoprotein and low-density lipoprotein, along with a decline in high-density lipoprotein levels. Although excessive levels of low density lipoprotein (LDL) are regarded to be the greatest predictors of an increased risk of developing atherosclerosis, dyslipidemia can also refer to raised levels of total cholesterol (TC) or triglycerides, or low level of high density lipoprotein cholesterol (HDL). Hyperlipidemia is also the major precursor of lipid related ailment such as atherosclerosis , coronary artery disease and also involved in sudden death syndrome. Introduction, categories for hyperlipidemia, signs, complications, pathophysiology, and therapy.
Key words : Hyperlipidemia, Fibrates, Statins, Squalene epoxidase inhibitors, Lanosterol synthase inhibitors, Diacyl glycerol acyl transferase inhibitors.

Cite This Article:

Please cite this article in press J S Venkatesh et al, An Introduction To Hyperlipidemia And Current Trends In Management Of Hyperlipidemia – A Review Article., Indo Am. J. P. Sci, 2023; 10(01).

Number of Downloads : 10

References:

1. Xu QY, Liu YH, Zhang Q, Ma B, Yang ZD, et al. (2014) Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats. Acta Pharmacologica Sinica 35: 1265.
2. Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, et al. (2004) Principles for national and regional guidelines on cardiovascular disease prevention: A scientific statement from the World Heart and Stroke Forum. Circulation 109: 3112-3121.
3. Jacobson MS (1998) Heart healthy diets for all children: No longer controversial. J Pediatr 133: 1-2.
4. Wells, G. B.,Dipiro, J., Schwinghammer, T., Hamilton, C. Phamacotherapy Handbook, 7thedn, USA, TheMcgraw Hill Companies, 2007; pp98-108.
5. Brouwers, M. C.,VanGreevenbroek, M. M.,Stehouwer, C. D.,de Graaf, J.,Stalenhoef, A. F. Thegenetics of familial combined hyperlipidaemia.Nat. Rev. Endocrinol., 8(6): 352-62 (2012).
6. Kumar, D., Parcha, V.,Maithani, A., Dhulia, I. Effect and evaluation of antihyperlipidemic activity guided isolated fraction from total methanol extract of Bauhinia variegata (linn.) in Triton WR–1339 induced hyperlipidemic rats. Asian Pac. J. Trop. Dis., 2(2): 909-913 (2012).
7. Joseph, D. Pharmacotherapy, A pathophysiological approach, 8thedn, The McGraw Hill companies, Inc. 2011; pp370.
8. Tripathi, K. D. Essentials of Medical Pharmacology, 6thedn, India: JP brothers medical publishers, pp613-614 (2008).
9. Wouters, K., Shiri-Sverdlov, R., van Gorp, P. J., van Bilsen, M., Hofker, M.H. Understanding hyperlipidemia and atherosclerosis: lessons from genetically modified apoe and ldlr mice.Clin. Chem. Lab. Med., 43(5):470-9 (2005).
10. Gao, W.,He, H. W, Wang, Z. M., Zhao, H., Xiao-Qing Lian, X. Q., Wang, Y. S., Zhu, J., Jian-Jun Yan, J. J., Zhang, D. G., Zhi-Jian Yang, Z. J., Wang, L. S. Plasma levels of lipometabolism-related miR-122 and miR370 are increased in patients with hyperlipidemia and associated with coronary artery disease.Lipids Health Dis., (11): 55 (2012).
11. Nickolas, T.L.,Radhakrishnan, J.,Appel, G.B. Hyperlipidemia and thrombotic complications in patients with membranous nephropathy.Semin.Nephrol.; 23(4):406-11 (2003).
12. Amarenco, P., Labreuche, J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol., 8 (5): 453 – 463 (2009).
13. Murphy SL, Xu J, Kochanek KD. Deaths: final data for 2010. Natl Vital Stat Rep. 2013 May 8;61(4):1-117. PMID: 24979972.
14. Ray KK, Seshasai SR, Erqou S. Statins and all-cause mortality in high-risk primary prevention: a meta analysis of 11 randomized controlled trials involving 65,229 participants. Arch Intern Med, 2010, 170(12), 1024-31.
15. Stone NJ, Robinson J, Lichtenstein AH, et al. ACC/AHAguideline on the treatment of blood cholesterol to reduce athero-sclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force1.
16. Hansen KE, Hildebrand JP, Ferguson EE, Stein JH. Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005;165:2671-6.
17. Eiland, L. S.,Luttrell, P. L. Use of statins for dyslipidemia in the pediatric population.J. Pediatr. Pharmacol. Therap., 15(3): 160–172 (2010).
18. Mahley, R. W., Bersot, T. P. Drug therapy for hypercholesterolemia and dyslipidemia, In: Hardman, J.G.; Limbird, L. E. and Gilman, A. G., Goodman & Gilman’s, The Pharmacological Basis of Therapeutics. 10thedn, New York: McGraw Hill, 2001; pp971–1002.
19. Bellosta, S.,Paoletti, R.,Corsini, A. Atherosclerosis: Evolving vascular biology and clinical implications, safety of statins: focus on clinical pharmacokinetics and drug interactions.Circulation., (109): 50-57 (2004).
20. Mills, E. J.,Wu, P.,Chong, G.,Ghement, I.,Singh, S.,Akl. E. A.,Eyawo, O.,Guyatt, G.,Berwanger, O., Briel, M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials.QJM., 104(2):109-124 (2011).
21. Abourbih S, Filion KB, Joseph L, Schiffrin EL, Rinfret S, Poirier P, Pilote L, Genest J, Eisenberg MJ. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med, 2009, 122(10), 962-962.
22. Kishor, S., Kathiravan, M., Somani, R., Shishoo, C.H. The biology and chemistry of hyperlipidemia.Bioorg. Med. Chem., 15(14): 4674-4699 (2007).
23. Singh R, Nain S. A Mini-Review on Hyperlipidemia: Common Clinical Problem. Interv Cardiol J 2018;Vol.4 No.3:11. doi:10.21767/2471-8157.100081.
24. . Safeer RS, Lacivita CL. Choosing drug therapy for patients with hyperlipidemia. Am Fam Physician. 2000 Jun 1;61(11):3371-82. PMID: 10865931.
25. Altmann, S. W., Davis, H. R., Zhu, L. J. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science., 303(5661): 1201–1204 (2004).
26. Shattat GF. A review article on hyperlipidemia: types, treatments and new drug targets. Biomedical and pharmacology journal. 2015 May 3;7(1):399-409. Doi: https://dx.doi.org/10.13005/bpj/504 .
27. Wong NN. Colesevelam: a new bile acid sequestrants. Heart disease, 2001, 3(1), 63-70
28. Arnold, M.A., Swanson, B.J., Crowder, C.D., Frankel, W.L., Lam-Himlin, D., Singhi, A.D., Stanich, P.P., Arnold, C.A. Colesevelam and colestipol: novel medication resins in the gastrointestinal tract. Am. J. Surg. Pathol.; 2014; 38(1).
29. MD, PhD Franklin J. Zieve et al. Results of the glucose-lowering effect of WelChol study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. clinthera.2007.01.003.
30. Pattis P, Wiedermann CJ. Ezetimibe-associated immune thrombocytopenia. Ann Pharmacother. 2008 Mar;42(3):430-3. doi: 10.1345/aph.1K614. Epub 2008 Feb 5. PMID: 18252832.